Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

See Also

Health Health / Illness, Injury & Treatments Health / Medical Practice Science & Technology / Biology & Life Sciences

Current Medical Articles

Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Pharmaceutical Executive May 1, 2012	Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
Pharmaceutical Executive May 1, 2012 William Looney	Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever.
Pharmaceutical Executive May 1, 2012	Super-Size Me Finding opportunities in the information explosion: big data, big challenges and big rewards.
Pharmaceutical Executive May 1, 2012	Managing Information Overload Pharmaceutical companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.
Pharmaceutical Executive May 1, 2012	Pharma's Winning Innovative Technology Highlighting the pharmaceutical companies awarded for exemplifying a high level of operational excellence with technology.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Pharmaceutical Executive May 1, 2012 Ben Comer	Comparing Apples to Broccoli In late March, the Supreme Court debated the merits or lack thereof of the Obama Administration's Patient Protection and Affordable Care Act. Can you match the analogy with the Justice?
Pharmaceutical Executive May 1, 2012	Best Practices: Commercial Analytics If the relationship between marketers and commercial analytics in the pharmaceutical and biotech sectors is leveraged properly, it can help marketers make more informed strategic decisions for their brands.
Pharmaceutical Executive May 1, 2012	Government: Big Pharma's Best Friend in Emerging Markets? To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.
Chemistry World May 8, 2012 Helen Carmichael	Pharma firms see mixed fortunes in Quebec Quebec's life sciences and pharmaceutical industry has suffered several blows in 2012, with hundreds of R&D jobs being lost. This comes despite the industry receiving hundreds of millions of dollars in government assistance and favorable tax rates.
Chemistry World May 4, 2012 Hayley Birch	What to do with leftover prescription drugs? Throwing away unused medication is kinder to the environment than returning it to the pharmacy, according to a new study.
Chemistry World May 3, 2012 Akshat Rathi	Ranbaxy launches new anti-malarial Synriam It is the first recently developed antimalarial that is not based on artemisinin, one of the most effective treatments for malaria, which has begun to suffer from problems with resistance in recent years.
Chemistry World May 2012	Biotech's bravura performer Bibiana Campos Seijo talks to scientist, philanthropist and serial entrepreneur Chris Evans, who is credited with having helped create the UK biotechnology industry.
CIO April 30, 2012 Stephanie Overby	Can Watson, IBM's Supercomputer, Cure Cancer? WellPoint and Cedars-Sinai are putting IBM's supercomputer Watson to the test in pilots targeting cancer treatment and improved EMRs.
Chemistry World April 26, 2012 Sarah Houlton	AstraZeneca seeks to refill dry pipeline with gout drug AstraZeneca is to acquire US-based Ardea Biosciences in a deal worth $1.26 billion. Its lead product, lesinurad, moved into Phase III trials at the end of last year for the management of patients suffering from gout.
Pharmaceutical Executive April 1, 2012	Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets.
Pharmaceutical Executive April 1, 2012	HBA Woman of the Year 2012 Progressions is a narrative about the commercial renewal that comes from embracing diversity, and there is no better symbol for that message than the Progressions series creator, Global Pharmaceutical Sector Leader Carolyn Buck-Luce.
Pharmaceutical Executive April 1, 2012	Ad Stars The campaigns chosen as this year's Pharm Exec Ad Stars include a diverse mix of clients, health conditions, and media channels.
Pharmaceutical Executive April 1, 2012 Jill Wechsler	Shortages and Sunshine Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Pharmaceutical Executive April 1, 2012 Ben Comer	Divided Kingdom What does a Scottish vote for independence mean for Big Pharma investment and healthcare funding and delivery in the UK?
Pharmaceutical Executive April 1, 2012 Jim Bedford	Navigating M&A Complexities Technical diligence is necessary to identify subsidiary connections. These must be cleverly unraveled and re-established to ensure successful carve-outs.
Pharmaceutical Executive April 1, 2012	Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more.
Pharmaceutical Executive April 1, 2012	Country Report: Ukraine Despite the severe blow to its economy, Ukraine has been recovering at a faster rate than its Western European counterparts. But what has such rapid development done for the country's healthcare?
Pharmaceutical Executive April 1, 2012	Special Section: Sunshine Act Still in the Shade Phase in of the Sunshine Act will force a reconsideration of the ethical consequences of all types of pharma meetings. How and to what extent remains to be seen.
Pharmaceutical Executive April 1, 2012 William Looney	IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Chemistry World April 3, 2012 Helen Gray	Mass spectrometry imaging: the new tool in counterfeit security The ever-increasing sophistication of the counterfeit trade is a growing economic problem, and when applied to pharmaceuticals, dangerous to human health.
Chemistry World April 2012 Derek Lowe	Column: In the Pipeline How long is 'too long' in the drug discovery game?
There are 8429 old articles available for this category.